BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 36744399)

  • 1. H3K27-altered diffuse midline glioma: a paradigm shifting opportunity in direct delivery of targeted therapeutics.
    Rechberger JS; Power BT; Power EA; Nesvick CL; Daniels DJ
    Expert Opin Ther Targets; 2023 Jan; 27(1):9-17. PubMed ID: 36744399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bench-to-bedside investigations of H3 K27-altered diffuse midline glioma: drug targets and potential pharmacotherapies.
    Rechberger JS; Bouchal SM; Power EA; Nonnenbroich LF; Nesvick CL; Daniels DJ
    Expert Opin Ther Targets; 2023; 27(11):1071-1086. PubMed ID: 37897190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
    Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
    J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.
    Castel D; Philippe C; Kergrohen T; Sill M; Merlevede J; Barret E; Puget S; Sainte-Rose C; Kramm CM; Jones C; Varlet P; Pfister SM; Grill J; Jones DTW; Debily MA
    Acta Neuropathol Commun; 2018 Nov; 6(1):117. PubMed ID: 30396367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Convection-Enhanced Delivery for Diffuse Intrinsic Pontine Glioma Treatment.
    Zhou Z; Singh R; Souweidane MM
    Curr Neuropharmacol; 2017; 15(1):116-128. PubMed ID: 27306036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Convection-Enhanced Delivery of Enhancer of Zeste Homolog-2 (EZH2) Inhibitor for the Treatment of Diffuse Intrinsic Pontine Glioma.
    Sasaki T; Katagi H; Goldman S; Becher OJ; Hashizume R
    Neurosurgery; 2020 Nov; 87(6):E680-E688. PubMed ID: 32674144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of an intratumoral cyst on drug distribution by convection-enhanced delivery: case report.
    Ivasyk I; Morgenstern PF; Wembacher-Schroeder E; Souweidane MM
    J Neurosurg Pediatr; 2017 Sep; 20(3):256-260. PubMed ID: 28686124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A combined approach of convection-enhanced delivery of peptide nanofiber reservoir to prolong local DM1 retention for diffuse intrinsic pontine glioma treatment.
    Bellat V; Alcaina Y; Tung CH; Ting R; Michel AO; Souweidane M; Law B
    Neuro Oncol; 2020 Oct; 22(10):1495-1504. PubMed ID: 32301996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diffuse midline glioma].
    Saito R
    No Shinkei Geka; 2022 Jan; 50(1):29-38. PubMed ID: 35169084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Strategies in Diffuse Midline Gliomas With the H3K27M Mutation: The Role of Convection-Enhanced Delivery in Overcoming Anatomic Challenges.
    Himes BT; Zhang L; Daniels DJ
    Front Oncol; 2019; 9():31. PubMed ID: 30800634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infusion-related side-effects during convection enhanced delivery for brainstem-diffuse midline glioma/diffuse intrinsic pontine glioma.
    Hollingworth M; Zacharoulis S
    J Neurooncol; 2022 Sep; 159(2):417-424. PubMed ID: 35933568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-time drug testing of paediatric diffuse midline glioma to support clinical decision making: The Zurich DIPG/DMG centre experience.
    Mueller T; Laternser S; Guerreiro Stücklin AS; Gerber NU; Mourabit S; Rizo M; Rushing EJ; Kottke R; Grotzer M; Krayenbühl N; Nazarian J; Mueller S
    Eur J Cancer; 2023 Jan; 178():171-179. PubMed ID: 36455411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developing chemotherapy for diffuse pontine intrinsic gliomas (DIPG).
    Gwak HS; Park HJ
    Crit Rev Oncol Hematol; 2017 Dec; 120():111-119. PubMed ID: 29198324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial.
    Souweidane MM; Kramer K; Pandit-Taskar N; Zhou Z; Haque S; Zanzonico P; Carrasquillo JA; Lyashchenko SK; Thakur SB; Donzelli M; Turner RS; Lewis JS; Cheung NV; Larson SM; Dunkel IJ
    Lancet Oncol; 2018 Aug; 19(8):1040-1050. PubMed ID: 29914796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Robot-guided convection-enhanced delivery of carboplatin for advanced brainstem glioma.
    Barua NU; Lowis SP; Woolley M; O'Sullivan S; Harrison R; Gill SS
    Acta Neurochir (Wien); 2013 Aug; 155(8):1459-65. PubMed ID: 23595829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABC Transporter Inhibition Plus Dexamethasone Enhances the Efficacy of Convection Enhanced Delivery in H3.3K27M Mutant Diffuse Intrinsic Pontine Glioma.
    Tsvankin V; Hashizume R; Katagi H; Herndon JE; Lascola C; Venkatraman TN; Picard D; Burrus B; Becher OJ; Thompson EM
    Neurosurgery; 2020 May; 86(5):742-751. PubMed ID: 31225627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming translational barriers in H3K27-altered diffuse midline glioma: Increasing the drug-tumor residence time.
    Power EA; Rechberger JS; Zhang L; Oh JH; Anderson JB; Nesvick CL; Ge J; Hinchcliffe EH; Elmquist WF; Daniels DJ
    Neurooncol Adv; 2023; 5(1):vdad033. PubMed ID: 37128506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status and advances to improving drug delivery in diffuse intrinsic pontine glioma.
    Arms LM; Duchatel RJ; Jackson ER; Sobrinho PG; Dun MD; Hua S
    J Control Release; 2024 May; 370():835-865. PubMed ID: 38744345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models.
    Vitanza NA; Biery MC; Myers C; Ferguson E; Zheng Y; Girard EJ; Przystal JM; Park G; Noll A; Pakiam F; Winter CA; Morris SM; Sarthy J; Cole BL; Leary SES; Crane C; Lieberman NAP; Mueller S; Nazarian J; Gottardo R; Brusniak MY; Mhyre AJ; Olson JM
    Neuro Oncol; 2021 Mar; 23(3):376-386. PubMed ID: 33130903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic avenues for targeting treatment challenges of diffuse midline gliomas.
    Noon A; Galban S
    Neoplasia; 2023 Jun; 40():100899. PubMed ID: 37030112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.